Last reviewed · How we verify
AMG 232
At a glance
| Generic name | AMG 232 |
|---|---|
| Sponsor | Kartos Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (PHASE1)
- Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (PHASE1)
- Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma (PHASE1)
- Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer (PHASE1)
- Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma (PHASE1)
- A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma (PHASE1)
- A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma (PHASE1)
- A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG 232 CI brief — competitive landscape report
- AMG 232 updates RSS · CI watch RSS
- Kartos Therapeutics, Inc. portfolio CI